NCT03851081View on ClinicalTrials.gov

Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

PHASE1/PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

January 21, 2021

Primary Completion Date

January 21, 2023

Study Completion Date

January 21, 2024

Conditions

Allogeneic Hematopoietic Stem Cell Transplantation RecipientBlasts 5 Percent or More of Bone Marrow Nucleated CellsBlasts 5 Percent or More of Peripheral Blood White CellsCD22 PositiveLymphoblasts 20 Percent or More of Bone Marrow Nucleated CellsLymphoblasts 20 Percent or More of Peripheral Blood White CellsRecurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL

Inotuzumab Ozogamicin

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

DRUG

Vincristine Sulfate Liposome

Given IV

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo